TY - JOUR
T1 - FD-MSGL
T2 - Drug Repositioning via Frequency-Domain Multi-Source Synergistic Graph Learning
AU - Zhu, Xiaobo
AU - Deng, Xun
AU - Zhang, Zimai
AU - Qi, Yujie
AU - Yin, Hengchuang
AU - Long, Xueyan
AU - Huang, Yu An
AU - Herget, Thomas
AU - Tan, Feng
AU - Hu, Lun
AU - You, Zhuhong
AU - Hu, Pengwei
N1 - Publisher Copyright:
© 2013 IEEE.
PY - 2026
Y1 - 2026
N2 - Drug repositioning accelerates therapeutic development by revealing novel indications for approved compounds, yet existing methods typically rely on single information sources and fail to integrate multi-scale biological mechanisms spanning molecular similarity, target selectivity, and multi-step regulatory pathways. Here we introduce FD-MSGL, a Frequency-Domain Multi-Source Synergistic Graph Learning framework that addresses this challenge by integrating three complementary biological information sources. FD-MSGL constructs homogeneous semantic graphs to capture molecular similarity in chemical space, heterogeneous graphs to model direct drug-protein-disease interactions revealing target selectivity, and pathway regulation graphs to trace indirect therapeutic mechanisms through multi-step regulatory cascades. Through frequency-domain decomposition, FD-MSGL simultaneously models local specificity of molecular recognition and global organizational patterns of drug families. The framework quantifies biological synergies across molecular, target, and pathway levels, integrates complementary evidence from chemical similarity, target selectivity, and regulatory mechanisms, and dynamically balances precise structural matching with global therapeutic pattern consistency. Empirical evaluation across three benchmark datasets demonstrates that FD-MSGL achieves competitive performance.
AB - Drug repositioning accelerates therapeutic development by revealing novel indications for approved compounds, yet existing methods typically rely on single information sources and fail to integrate multi-scale biological mechanisms spanning molecular similarity, target selectivity, and multi-step regulatory pathways. Here we introduce FD-MSGL, a Frequency-Domain Multi-Source Synergistic Graph Learning framework that addresses this challenge by integrating three complementary biological information sources. FD-MSGL constructs homogeneous semantic graphs to capture molecular similarity in chemical space, heterogeneous graphs to model direct drug-protein-disease interactions revealing target selectivity, and pathway regulation graphs to trace indirect therapeutic mechanisms through multi-step regulatory cascades. Through frequency-domain decomposition, FD-MSGL simultaneously models local specificity of molecular recognition and global organizational patterns of drug families. The framework quantifies biological synergies across molecular, target, and pathway levels, integrates complementary evidence from chemical similarity, target selectivity, and regulatory mechanisms, and dynamically balances precise structural matching with global therapeutic pattern consistency. Empirical evaluation across three benchmark datasets demonstrates that FD-MSGL achieves competitive performance.
KW - Drug repositioning
KW - Frequency-domain analysis
KW - Graph neural networks
KW - Heterogeneous biological networks
KW - Multi-source synergistic learning
UR - https://www.scopus.com/pages/publications/105037974804
U2 - 10.1109/JBHI.2026.3688381
DO - 10.1109/JBHI.2026.3688381
M3 - 文章
C2 - 42048211
AN - SCOPUS:105037974804
SN - 2168-2194
JO - IEEE Journal of Biomedical and Health Informatics
JF - IEEE Journal of Biomedical and Health Informatics
ER -